Natural Product (NP) Details
| General Information of the NP (ID: NP6711) | |||||
|---|---|---|---|---|---|
| Name |
Glucocorticoids
|
||||
| Species Origin | Homo sapiens ... | Click to Show/Hide | |||
| Homo sapiens | |||||
| Disease | Thyrotoxicosis [ICD-11: 5A02] | Phase 3 | [1] | ||
| ADMET Property |
Absporption
Caco-2 Permeability
-4.796
MDCK Permeability
-4.548
PAMPA
- - -
HIA
- - -
Distribution
VDss
0.57
PPB
97.4%
BBB
+++
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
- - -
CYP2C19 inhibitor
-
CYP2C19 substrate
- - -
CYP2C9 inhibitor
+++
CYP2C9 substrate
- - -
CYP2D6 inhibitor
++
CYP2D6 substrate
+
CYP3A4 inhibitor
- - -
CYP3A4 substrate
+++
CYP2B6 inhibitor
- - -
CYP2B6 substrate
- - -
CYP2C8 inhibitor
+++
HLM Stability
- -
Excretion
CLplasma
6.876
T1/2
0.432
Toxicity
DILI
- -
Rat Oral Acute Toxicity
-
FDAMDD
+++
Respiratory
+
Human Hepatotoxicity
++
Ototoxicity
++
Drug-induced Nephrotoxicity
+++
Drug-induced Neurotoxicity
+++
Hematotoxicity
- -
Genotoxicity
+++
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Selumetinib | Melanoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BCL2L11 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Cells derived from acute lymphoblastic leukemia patients | Acute lymphoblastic leukemia | Homo sapiens | |||
| In-vivo Model | For a xenograft model, primagraft cells were injected intrafemorally into NOD SCID Gamma null (NSG) mice. | |||||
| Experimental
Result(s) |
A selumetinib-dexamethasone combination may be highly effective in RAS pathway-mutated acute lymphoblastic leukemia. | |||||
